Zhiwei Liu1, Ellen T Chang2,3, Qing Liu4,5, Yonglin Cai6,7, Zhe Zhang8,9, Guomin Chen10, Qi-Hong Huang11, Shang-Hang Xie4,5, Su-Mei Cao4,5, Jian-Yong Shao5, Wei-Hua Jia5, Yuming Zheng6,7, Jian Liao12, Yufeng Chen9, Longde Lin9, Liming Liang13,14, Ingemar Ernberg15, Thomas L Vaughan16,17, Hans-Olov Adami1,13, Guangwu Huang8,9, Yi Zeng10, Yi-Xin Zeng5,18, Weimin Ye1. 1. Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden. 2. Exponent Inc, Health Sciences Practice, Menlo Park, California. 3. Division of Epidemiology, Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California. 4. Department of Cancer Prevention Center, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China. 5. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China. 6. Department of Clinical Laboratory, Wuzhou Red Cross Hospital, Wuzhou, Guangxi, China. 7. Wuzhou Health System Key Laboratory for Nasopharyngeal Carcinoma Etiology and Molecular Mechanism, Wuzhou, Guangxi, China. 8. Department of Otolaryngology-Head and Neck Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China. 9. Key Laboratory of High-Incidence Tumor Prevention and Treatment, Guangxi Medical University, Ministry of Education, Nanning, Guangxi, China. 10. State Key Laboratory for Infectious Diseases Prevention and Control, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China. 11. Sihui Cancer Institute Sihui, Guangdong, China. 12. Cangwu Institute for Nasopharyngeal Carcinoma Control and Prevention, Wuzhou, Guangxi, China. 13. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. 14. Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. 15. Department of Microbiology, Tumor and Cell Biology Karolinska Institute, Stockholm, Sweden. 16. Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. 17. Department of Epidemiology, University of Washington, Seattle, Washington. 18. Beijing Hospital, Beijing, China.
Abstract
BACKGROUND: To the authors' knowledge, no studies to date have explored familial risks of nasopharyngeal carcinoma (NPC) in detail and quantified its lifetime risk in high-incidence populations. METHODS: The authors conducted a population-based case-control study of 2499 NPC cases and 2576 controls randomly selected in southern China from 2010 through 2014. Unconditional logistic regression was used to estimate multivariable-adjusted odds ratios (ORs) with 95% confidence intervals (95% CIs) associated with a family history of NPC. In addition, the authors compiled a reconstructed cohort comprising 40,781 first-degree relatives of cases and controls to calculate the lifetime cumulative risk of NPC. RESULTS: Individuals with a first-degree family history of NPC were found to be at a >4-fold risk of NPC (OR, 4.6; 95% CI, 3.5-6.1) compared with those without such a history, but had no excess risk of other malignancies. The excess risk was higher for a maternal than a paternal history and was slightly stronger for a sibling compared with a parental history, and for a sororal than a fraternal history. Among relatives of cases, the cumulative risk of NPC up to age 74 years was 3.7% (95% CI, 3.3%-4.2%), whereas that among relatives of controls was 0.9% (95% CI, 0.7%-1.2%). Cumulative risk was higher in siblings than in parents among relatives of cases, whereas no such difference was noted among relatives of controls. CONCLUSIONS: Individuals with a family history of NPC have a substantially higher risk of NPC. These relative and cumulative risk estimates can guide the development of strategies for early detection and clinical consultation in populations with a high incidence of NPC. Cancer 2017;123:2716-25.
BACKGROUND: To the authors' knowledge, no studies to date have explored familial risks of nasopharyngeal carcinoma (NPC) in detail and quantified its lifetime risk in high-incidence populations. METHODS: The authors conducted a population-based case-control study of 2499 NPC cases and 2576 controls randomly selected in southern China from 2010 through 2014. Unconditional logistic regression was used to estimate multivariable-adjusted odds ratios (ORs) with 95% confidence intervals (95% CIs) associated with a family history of NPC. In addition, the authors compiled a reconstructed cohort comprising 40,781 first-degree relatives of cases and controls to calculate the lifetime cumulative risk of NPC. RESULTS: Individuals with a first-degree family history of NPC were found to be at a >4-fold risk of NPC (OR, 4.6; 95% CI, 3.5-6.1) compared with those without such a history, but had no excess risk of other malignancies. The excess risk was higher for a maternal than a paternal history and was slightly stronger for a sibling compared with a parental history, and for a sororal than a fraternal history. Among relatives of cases, the cumulative risk of NPC up to age 74 years was 3.7% (95% CI, 3.3%-4.2%), whereas that among relatives of controls was 0.9% (95% CI, 0.7%-1.2%). Cumulative risk was higher in siblings than in parents among relatives of cases, whereas no such difference was noted among relatives of controls. CONCLUSIONS: Individuals with a family history of NPC have a substantially higher risk of NPC. These relative and cumulative risk estimates can guide the development of strategies for early detection and clinical consultation in populations with a high incidence of NPC. Cancer 2017;123:2716-25.
Authors: Shao-Hua Xie; Ignatius Tak-Sun Yu; Lap Ah Tse; Joseph Siu Kie Au; June Sze Man Lau Journal: Cancer Causes Control Date: 2015-03-31 Impact factor: 2.506
Authors: Minzhong Tang; James A Lautenberger; Xiaojiang Gao; Efe Sezgin; Sher L Hendrickson; Jennifer L Troyer; Victor A David; Li Guan; Carl E McIntosh; Xiuchan Guo; Yuming Zheng; Jian Liao; Hong Deng; Michael Malasky; Bailey Kessing; Cheryl A Winkler; Mary Carrington; Guy Dé The; Yi Zeng; Stephen J O'Brien Journal: PLoS Genet Date: 2012-11-29 Impact factor: 5.917
Authors: Katelyn O Stepan; Angela L Mazul; S Andrew Skillington; Randal C Paniello; Jason T Rich; Jose P Zevallos; Ryan S Jackson; Patrik Pipkorn; Sean Massa; Sidharth V Puram Journal: Head Neck Date: 2021-02-23 Impact factor: 3.821
Authors: Simon I Okekpa; Rabiatul Basria S M N Mydin; Ernest Mangantig; Nor Syaffaf Amaliana Azmi; Siti Nur Syahirah Zahari; Gurjeet Kaur; Yusri Musa Journal: Asian Pac J Cancer Prev Date: 2019-11-01